]>
IRCT20200718048129N1 IRCT 2020-08-11 Iran University of Medical Sciences Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caugh caused by COVID-19 in recovery phase Evaluation and comparison of the effectiveness of Hydroxychloroquin versus Clarithromycin in recovery of dyspnea and Caugh at the end of the acute phase of COVID-19 treatment 2020-08-22 anticipated 45 Complete https://irct.ir/trial/49729 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In our study, the simple randomization method is used as follows. A number of sealed envelopes in which study groups with letters A, intervention group with hydroxychloroquine, group B, intervention with clarithromycin and group C, including the control group, have been identified.The number of envelopes in each group is equal in number. The cards are merged and a card is randomly selected for each referring patient, thus assigning the patient to one of the groups. The removed card is then returned to the other cards. This process continues until a random sequence is reached according to the sample size in each group. 3 COVID-19. Intervention 1: Intervention group 1: Hydroxychloroquine tablets 200 mg every 12 hours for one month fram Rooz daroo company. Intervention 2: Intervention group 2: Clarithromycin 500 mg capsules every 12 hours for one month from Tehran shimi company. Intervention 3: Control group: without receiving medication during a one-month follow-up. Yes - There is a plan to make this available What will be shared: All provided data after unidentifying the subjects, include demographic information and characteristics of their disease in the acute phase, along with a description of the first visit and tests taken from patients at that time. The type of performed intervention for each patient and patients' clinical condition change after Intervention practices and finally the method of data analysis are the other documents which can be provided. When: Access started 6 months after the results were published To whom: Researchers working in academic and scientific institutions Conditions: In order to conduct further research, any analysis other than those used in this study is acceptable with the permission of the research agent. Where to obtain: Dr. Sima Bahrami Address: Allergy and Immunology Clinic,Hazrat Rasoul Hospital, Niayesh St - Sattarkhan Av. Tehran Phone: 09127305773 Email: bahrami.s@iums.ac.ir How to obtain: The applicant can introduce himself / herself by e-mail and provide sufficient and documented reasons for receiving the study information.The research agent can check this information in a period of two weeks and if he is sure that the request is correct, he will send the requested items to the applicant Comments:
public Sima Bahrami
Hazrate Rasoole Akram hospital,Niayesh St,Satarkhan Av,Tehran
Tehran Iran (Islamic Republic of) 1445613131 +98 21 6435 1000 bahrami.s@iums.ac.ir Iran University of Medical Sciences scientific Sima Bahrami
Allergy and immunology clinic,Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av,Tehran
Tehran Iran (Islamic Republic of) 1445613131 +98 21 6435 1000 bahrami.s@iums.ac.ir Iran University of Medical Sciences Iran (Islamic Republic of) Patients with definitive diagnosis of COVID19 were hospitalized and treated Patients with COVID19 who still have dyspena and cough two weeks after discharge from the hospital Patients with COVID19 who continue to have lung involvement on CT SCAN two weeks after discharge 20 years 50 years Both Patients with comorbidities such as chronic heart or lung disease before COVID19 The need for long-term use of drugs that have an irreversible interaction with the drugs used in the plan. U07.1 COVID19 ,virus identified Treatment - Other Treatment - Other Treatment - Other Intervention group 1: Hydroxychloroquine tablets 200 mg every 12 hours for one month fram Rooz daroo company Intervention group 2: Clarithromycin 500 mg capsules every 12 hours for one month from Tehran shimi company Control group: without receiving medication during a one-month follow-up Dyspnea. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: Medical Research Council(MRC). Cough. Timepoint: Beginning of the study (before the intervention), 14, 30 days after the start of the study. Method of measurement: visual analogue scale(vas). Lung function. Timepoint: At the beginning of the study (before the intervention) and 30 days later at the end of the study. Method of measurement: six minute walk test(6MW). Iran University of Medical Sciences Approved 2020-07-04 Ethics committee of Iran university of Medical Sciences Floor5,Headquarters,Iran university of Medical science,between Chamran and sheikh Fazlollah,Hemmat Highway,Tehran Tehran Tehran Iran (Islamic Republic of)